Literature DB >> 3932213

Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa.

M A Luzar, T C Montie.   

Abstract

Twenty Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in good and poor clinical condition were typed by the American Scientific (Difco Laboratories, Detroit, Mich.) Typing Scheme. Only five strains were agglutinated with a single typing serum. Ten strains were agglutinated with more than one serum, and five were not agglutinated with any serum, suggesting some type of lipopolysaccharide alteration in the majority of these strains. Of the strains from patients in good clinical condition, 72% demonstrated proteolytic activity, while 60% of the strains from patients in poor clinical condition demonstrated no proteolytic activity. Twenty-three cystic fibrosis strains of P. aeruginosa examined demonstrated reduced bacteremic virulence when compared with a virulent burn strain with a 50% lethal dose (LD50) of 1.5 X 10(1) CFU in an invasive burned mouse model. Ninety-two percent of the strains tested were avirulent at doses of 10(3) to 10(5) CFU. The LD50s were determined for 10 selected strains which exhibited specific important morphological and physiological deficiencies. Five of the strains tested gave LD50s greater than 10(6) CFU. Reduced virulence of these strains was associated with loss of two or more physiological characteristics associated with virulence. The cystic fibrosis strains of P. aeruginosa which morphologically and physiologically resembled the virulent burn strain were the most virulent (LD50s of 10(2) to 10(4). Results suggest that some degree of virulence is associated only with classic strains prevalent in early infections. The data suggest that a selection transition occurs in the lungs of patients with cystic fibrosis that favors P. aeruginosa avirulence. The avirulent state may be caused by alterations in the cell envelope, including associated factors such as motility and chemotaxis and protease production.

Entities:  

Mesh:

Year:  1985        PMID: 3932213      PMCID: PMC261994          DOI: 10.1128/iai.50.2.572-576.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  The specificity of agglutination reactions of Pseudomonas aeruginosa with O antisera.

Authors:  T L Pitt; Y J Erdman
Journal:  J Med Microbiol       Date:  1978-02       Impact factor: 2.472

2.  A report on sixty-five patients over 17 years of age.

Authors:  H Shwachman; L L Kulczycki; K T Khaw
Journal:  Pediatrics       Date:  1965-11       Impact factor: 7.124

3.  Asymptomatic bacteriuria in schoolgirls. II. Differences in escherichia coli causing asymptomatic bacteriuria.

Authors:  U Lindberg; L A Hanson; U Jodal; G Lidin-Janson; K Lincoln; S Olling
Journal:  Acta Paediatr Scand       Date:  1975-05

4.  The relationship between the O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes.

Authors:  I R Chester; P M Meadow; T L Pitt
Journal:  J Gen Microbiol       Date:  1973-10

Review 5.  Research in cystic fibrosis (third of three parts).

Authors:  P A di Sant'Agnese; P B Davis
Journal:  N Engl J Med       Date:  1976-09-09       Impact factor: 91.245

6.  Pseudomonas carrier rates of patients with cystic fibrosis and of members of their families.

Authors:  L R Laraya-Cuasay; K R Cundy; N N Huang
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

7.  In vivo studies on protease and elastase from Pseudomonas aeruginosa.

Authors:  K Kawaharajo; J Y Homma; Y Aoyama; K Morihara
Journal:  Jpn J Exp Med       Date:  1975-04

8.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

9.  Serological typing of Pseudomonas aeruginosa: use of commercial antisera and live antigens.

Authors:  C D Brokopp; R Gomez-Lus; J J Farmer
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

10.  Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition.

Authors:  M A Luzar; M J Thomassen; T C Montie
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

View more
  33 in total

1.  Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE).

Authors:  H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Determination of the regulon and identification of novel mRNA targets of Pseudomonas aeruginosa RsmA.

Authors:  Anja Brencic; Stephen Lory
Journal:  Mol Microbiol       Date:  2009-05       Impact factor: 3.501

3.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Growth-dependent alterations in production of serotype-specific and common antigen lipopolysaccharides in Pseudomonas aeruginosa PAO1.

Authors:  E J McGroarty; M Rivera
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

Review 6.  Regulation of bacterial virulence by Csr (Rsm) systems.

Authors:  Christopher A Vakulskas; Anastasia H Potts; Paul Babitzke; Brian M M Ahmer; Tony Romeo
Journal:  Microbiol Mol Biol Rev       Date:  2015-06       Impact factor: 11.056

7.  Aeration selects for mucoid phenotype of Pseudomonas aeruginosa.

Authors:  D P Krieg; J A Bass; S J Mattingly
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

8.  Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis.

Authors:  E Mahenthiralingam; M E Campbell; D P Speert
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.

Authors:  Lei Yang; Janus A J Haagensen; Lars Jelsbak; Helle Krogh Johansen; Claus Sternberg; Niels Høiby; Søren Molin
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

10.  Parallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo.

Authors:  Holly K Huse; Taejoon Kwon; James E A Zlosnik; David P Speert; Edward M Marcotte; Marvin Whiteley
Journal:  MBio       Date:  2010-09-21       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.